TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03747120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: All subjects will receive Paclitaxel weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All subjects will receive Paclitaxel weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All subjects will receive Paclitaxel weekly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: All subjects will receive Trastuzumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: All subjects will receive Trastuzumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: All subjects will receive Trastuzumab every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Arm A and Arm B subjects will receive Pertuzumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Arm A and Arm B subjects will receive Pertuzumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
Study: NCT02878915

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided femoral puncture
Study: NCT04606004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool application
Description: Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
Study: NCT01345006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells
Study: NCT01597388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
Study: NCT00187122

Intervention type: DRUG
Group type: OTHER
Intervention: Daunomycin
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: L-Asparaginase
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Mercaptopurine
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: See Detailed Description section for description of treatment plan.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: See Detailed Description section for description of treatment plan.
Study: NCT02520414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphion® Bipolar Hysteroscopic Tissue Resection System
Study: NCT03126721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: a single oral dose of 2 mg midazolam
Study: NCT04606004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care skincare
Description: Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A\&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care skincare
Description: Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A\&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin.
Study: NCT00648115

Intervention type: OTHER
Group type: OTHER
Intervention: Basic Vocational Services
Description: Vocational services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Study
Description: Veteran receives self-study resources

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Program
Description: Veteran participates in group vocational program
Study: NCT00597662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polylactide-caprolactone-trimethylenecarbonate copolymer
Description: Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Icodextrin 4%
Description: 1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
Study: NCT01912586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vacuum erection device
Description: sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vacuum erection device
Description: sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
Study: NCT01184820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Description: Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
Study: NCT03215290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCS
Description: The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle.
Study: NCT03283787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroMatrix® and Cytal™ Wound Matrix 2-Layer
Description: MicroMatrix® and Cytal™ Wound Matrix 2-Layer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
Description: MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
Study: NCT01597388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: IM monthly after loading dose
Study: NCT05008354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine
Description: Pyridoxine tablet 40mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study: NCT01640808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIK-333(peretinoin)
Description: 600mg (8 x 75mg capsules) orally, twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (8 x Placebo capsules) orally, twice a day
Study: NCT06292455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic resistance training
Description: six-weeks elastic resistance training of upper limb. Three days per week. volume per session would be 10 repetitions and three sets. 2 minute rest interval between each set.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Resistance Training
Description: players follow their routine exercise protocol
Study: NCT01903473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T regulatory cells
Description: One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs.
Study: NCT03257826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kirschner wire
Description: retrograde percutaneous kirschner wire was applied to stabilize the tibia.
Study: NCT02284438

Intervention type: DEVICE
Group type: OTHER
Intervention: Endotracheal tube
Description: Three endotracheal tubes with different surfaces will be used
Study: NCT04347681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: convalescent plasma from recovered COVID 19 donor
Description: After obtaining informed consent, Eligible Patients who have severe COVID-19 and have not recovered yet will be infused with the donated convalescent plasma (10-15 ml/kg body weight of recipient)19 at least once \& if possible, daily, for up to 5 sessions.
Study: NCT03283787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: Negative Pressure Wound Therapy
Study: NCT03355131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted NASA's Mission X program
Description: 8 Weeks Adapted National Aeronautics and Space Administration's (NASA's) Mission X (MX) program
Study: NCT03691051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus Capecitabine
Description: Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
Study: NCT00430573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
Study: NCT01245959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, cisplatin and fluorouracil
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT01081262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01989585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT01245959

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Study: NCT01989585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo multigated acquisition scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo multigated acquisition scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT01904448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Implantation in Children
Study: NCT01856192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04668079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified cross body stretch
Description: Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given
Study: NCT03126721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: a single oral dose of 2 mg midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06751979
Description: multiple oral doses of PF-06751979 100 mg a day
Study: NCT04668079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sleeper stretch
Description: Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given
Study: NCT00027066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Aspirin
Description: 325mg tablet daily
Study: NCT00974402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
Study: NCT04260984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided injection
Description: For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palpation-guided injection
Description: Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
Study: NCT00737997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 ml saline alone
Study: NCT00226746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine
Description: Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36.
Study: NCT00881972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: walking/running/cycling
Study: NCT01150500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-4107 Zotarolimus-Eluting Coronary Stent
Study: NCT01313299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Study: NCT02433392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CM-BC2
Description: CM-BC2 is a drug-eluting bead, a drug-device combination
Study: NCT05110651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
Study: NCT04083690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
Description: Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
Description: Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.